Iron, oxidative stress, and redox signaling in the cardiovascular system

Molecular Nutrition and Food Research

Volumn 58, Issue 8, 2014, Pages 1721-1738

  Gudjoncik, Aurélie ^a,b   Guenancia, Charles ^a,b   Zeller, Marianne ^a   Cottin, Yves ^a,b   Vergely, Catherine ^a   Rochette, Luc ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

Cardiovascular; Disease; Iron; Oxidative stress; Redox

Indexed keywords

IRON INTAKE; OXIDIZING AGENT;

ANIMAL; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMAN; INTOXICATION; IRON INTAKE; IRON OVERLOAD; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; IRON OVERLOAD; IRON, DIETARY; OXIDANTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84905386350     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201400036     Document Type: Article

References (146)

1. Rochette, L., Tatou, E., Vergely, C., Maupoil, V. et al., Regional heterogeneity of decreased myocardial norepinephrine and increased lipid peroxidation levels in patients with end-stage failing heart secondary to dilated or ischemic cardiomyopathy. J. Heart Lung Transplant. 2008, 27, 767-774.
2. Tsutsui, H., Kinugawa, S., Matsushima, S., Oxidative stress and heart failure. Am. J. Physiol. Heart Circ. Physiol. 2011, 301, H2181-H2190.
3. Rochette, L., Tatou, E., Maupoil, V., Zeller, M. et al., Atrial and vascular oxidative stress in patients with heart failure. Cell. Physiol. Biochem. 2011, 27, 497-502.
4. Koskenkorva-Frank, T. S., Weiss, G., Koppenol, W. H., Burckhardt, S., The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic. Biol. Med. 2013, 65, 1174-1194.
5. Santos, C. X., Anilkumar, N., Zhang, M., Brewer, A. C. et al., Redox signaling in cardiac myocytes. Free Radic. Biol. Med. 2011, 50, 777-793.
6. Brissot, P., Ropert, M., Le Lan, C., Loreal, O., Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim. Biophys. Acta 2012, 1820, 403-410.
7. Schafer, F. Q., Buettner, G. R., Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 2001, 30, 1191-1212.
8. Giustarini, D., Dalle-Donne, I., Tsikas, D., Rossi, R., Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit. Rev. Clin. Lab. Sci. 2009, 46, 241-281.
9. Halliwell, B., Gutteridge, J. M., The definition and measurement of antioxidants in biological systems. Free Radic. Biol. Med. 1995, 18, 125-126.
10. Vergely, C., Maupoil, V., Clermont, G., Bril, A. et al., Identification and quantification of free radicals during myocardial ischemia and reperfusion using electron paramagnetic resonance spectroscopy. Arch. Biochem. Biophys. 2003, 420, 209-216.
11. Montezano, A. C., Touyz, R. M., Reactive oxygen species and endothelial function-role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin. Pharmacol. Toxicol. 2012, 110, 87-94.
12. Oudot, A., Martin, C., Busseuil, D., Vergely, C. et al., NADPH oxidases are in part responsible for increased cardiovascular superoxide production during aging. Free Radic. Biol. Med. 2006, 40, 2214-2222.
13. Richard, C., Lauzier, B., Delemasure, S., Talbot, S. et al., Effects of angiotensin-1 converting enzyme inhibition on oxidative stress and bradykinin receptor expression during doxorubicin-induced cardiomyopathy in rats. J. Cardiovasc. Pharmacol. 2008, 52, 278-285.
14. Lyle, A. N., Griendling, K. K., Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology 2006, 21, 269-280.
15. Schramm, A., Matusik, P., Osmenda, G., Guzik, T. J., Targeting NADPH oxidases in vascular pharmacology. Vascul. Pharmacol. 2012, 56, 216-231.
16. Gkaliagkousi, E., Ferro, A., Nitric oxide signalling in the regulation of cardiovascular and platelet function. Front. Biosci. 2011, 16, 1873-1897.
17. Lorin, J., Zeller, M., Guilland, J. C., Cottin, Y. et al., Arginine and nitric oxide synthase: regulatory mechanisms and cardiovascular aspects. Mol. Nutr. Food Res. 2013.
18. Madamanchi, N. R., Runge, M. S., Redox signaling in cardiovascular health and disease. Free Radic. Biol. Med. 2013, 61C, 473-501.
19. Halliwell, B., Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward? Cardiovasc. Res. 2000, 47, 410-418.
20. Ghibu, S., Richard, C., Vergely, C., Zeller, M. et al., Antioxidant properties of an endogenous thiol: alpha-lipoic acid, useful in the prevention of cardiovascular diseases. J. Cardiovasc. Pharmacol. 2009, 54, 391-398.
21. Rochette, L., Ghibu, S., Richard, C., Zeller, M. et al., Direct and indirect antioxidant properties of alpha-lipoic acid and therapeutic potential. Mol. Nutr. Food. Res. 2013, 57, 114-125.
22. Li, H., Horke, S., Forstermann, U., Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol. Sci. 2013, 34, 313-319.
23. Schopfer, F. J., Cipollina, C., Freeman, B. A., Formation and signaling actions of electrophilic lipids. Chem. Rev. 2011, 111, 5997-6021.
24. Riggins, J. N., Marnett, L. J., Mutagenicity of the malondialdehyde oligomerization products 2-(3'-oxo-1'-propenyl)-malondialdehyde and 2, 4-dihydroxymethylene-3-(2, 2-dimethoxyethyl)glutaraldehyde in Salmonella. Mutat. Res. 2001, 497, 153-157.
25. Halliwell, B., Free radicals and antioxidants-quo vadis? Trends Pharmacol. Sci. 2011, 32, 125-130.
26. Sharma, M. K., Buettner, G. R., Interaction of vitamin C and vitamin E during free radical stress in plasma: an ESR study. Free Radic. Biol. Med. 1993, 14, 649-653.
27. Rines, A. K., Ardehali, H., Transition metals and mitochondrial metabolism in the heart. J. Mol. Cell. Cardiol. 2013, 55, 50-57.
28. Terman, A., Kurz, T., Lysosomal iron, iron chelation, and cell death. Antioxid. Redox. Signal. 2013, 18, 888-898.
29. Uriu-Adams, J. Y., Keen, C. L., Copper, oxidative stress, and human health. Mol. Aspects Med. 2005, 26, 268-298.
30. Wenzel, P., Schuhmacher, S., Kienhofer, J., Muller, J. et al., Manganese superoxide dismutase and aldehyde dehydrogenase deficiency increase mitochondrial oxidative stress and aggravate age-dependent vascular dysfunction. Cardiovasc. Res. 2008, 80, 280-289.
31. Brigelius-Flohe, R., Maiorino, M., Glutathione peroxidases. Biochim. Biophys. Acta 2013, 1830, 3289-3303.
32. Sengupta, R., Holmgren, A., Thioredoxin and thioredoxin reductase in relation to reversible S-nitrosylation. Antioxid. Redox. Signal. 2013, 18, 259-269.
33. Brown, G. C., Borutaite, V., There is no evidence that mitochondria are the main source of reactive oxygen species in mammalian cells. Mitochondrion 2012, 12, 1-4.
34. Camara, A. K., Bienengraeber, M., Stowe, D. F., Mitochondrial approaches to protect against cardiac ischemia and reperfusion injury. Front. Physiol. 2011, 2, 13.
35. Drose, S., Brandt, U., Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv. Exp. Med. Biol. 2012, 748, 145-169.
36. Paradies, G., Petrosillo, G., Paradies, V., Ruggiero, F. M., Oxidative stress, mitochondrial bioenergetics, and cardiolipin in aging. Free Radic. Biol. Med. 2010, 48, 1286-1295.
37. Javadov, S., Kuznetsov, A., Mitochondrial permeability transition and cell death: the role of cyclophilin d. Front. Physiol. 2013, 4, 76.
38. Kanai, A. J., Pearce, L. L., Clemens, P. R., Birder, L. A. et al., Identification of a neuronal nitric oxide synthase in isolated cardiac mitochondria using electrochemical detection. Proc. Natl. Acad. Sci. USA 2001, 98, 14126-14131.
39. Bouton, C., Chauveau, M. J., Lazereg, S., Drapier, J. C., Recycling of RNA binding iron regulatory protein 1 into an aconitase after nitric oxide removal depends on mitochondrial ATP. J. Biol. Chem. 2002, 277, 31220-31227.
40. Zaobornyj, T., Ghafourifar, P., Strategic localization of heart mitochondrial NOS: a review of the evidence. Am. J. Physiol. Heart Circ. Physiol. 2012, 303, H1283-H1293.
41. Weiss, G., Goodnough, L. T., Anemia of chronic disease. N. Engl. J. Med. 2005, 352, 1011-1023.
42. Qunibi, W. Y., The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 2010, 60, 399-412.
43. Heath, A. L., Fairweather-Tait, S. J., Clinical implications of changes in the modern diet: iron intake, absorption and status. Best Pract. Res. Clin. Haematol. 2002, 15, 225-241.
44. Lim, H. H., Yang, S. J., Kim, Y., Lee, M. et al., Combined treatment of mulberry leaf and fruit extract ameliorates obesity-related inflammation and oxidative stress in high fat diet-induced obese mice. J. Med. Food 2013, 16, 673-680.
45. Sharp, P. A., Intestinal iron absorption: regulation by dietary & systemic factors. Int. J. Vitam. Nutr. Res. 2010, 80, 231-242.
46. Latunde-Dada, G. O., Simpson, R. J., McKie, A. T., Recent advances in mammalian haem transport. Trends Biochem. Sci. 2006, 31, 182-188.
47. Ishizuka, M., Abe, F., Sano, Y., Takahashi, K. et al., Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy. Int. Immunopharmacol. 2011, 11, 358-365.
48. Byrne, S. L., Krishnamurthy, D., Wessling-Resnick, M., Pharmacology of iron transport. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 17-36.
49. Tenhunen, R., Marver, H. S., Schmid, R., Microsomal heme oxygenase. Characterization of the enzyme. J. Biol. Chem. 1969, 244, 6388-6394.
50. Rochette, L., Cottin, Y., Zeller, M., Vergely, C., Carbon monoxide: mechanisms of action and potential clinical implications. Pharmacol. Ther. 2013, 137, 133-152.
51. West, A. R., Oates, P. S., Subcellular location of heme oxygenase 1 and 2 and divalent metal transporter 1 in relation to endocytotic markers during heme iron absorption. J. Gastroenterol. Hepatol. 2008, 23, 150-158.
52. Varfaj, F., Lampe, J. N., Ortiz de Montellano, P. R., Role of cysteine residues in heme binding to human heme oxygenase-2 elucidated by two-dimensional NMR spectroscopy. J. Biol. Chem. 2012, 287, 35181-35191.
53. Hayashi, S., Omata, Y., Sakamoto, H., Higashimoto, Y. et al., Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. Gene 2004, 336, 241-250.
54. Buehler, P. W., Alayash, A. I., Redox biology of blood revisited: the role of red blood cells in maintaining circulatory reductive capacity. Antioxid. Redox. Signal. 2005, 7, 1755-1760.
55. Iancu, T. C., Ultrastructural aspects of iron storage, transport and metabolism. J. Neural. Transm. 2011, 118, 329-335.
56. Anderson, G. J., Vulpe, C. D., Mammalian iron transport. Cell. Mol. Life Sci. 2009, 66, 3241-3261.
57. Bayeva, M., Chang, H. C., Wu, R., Ardehali, H., When less is more: novel mechanisms of iron conservation. Trends Endocrinol. Metab. 2013, 24, 569-577.
58. Knutson, M. D., Iron-sensing proteins that regulate hepcidin and enteric iron absorption. Annu. Rev. Nutr. 2010, 30, 149-171.
59. McKie, A. T., Barrow, D., Latunde-Dada, G. O., Rolfs, A. et al., An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 2001, 291, 1755-1759.
60. Frazer, D. M., Anderson, G. J., Iron imports. I. Intestinal iron absorption and its regulation. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289, G631-G635.
61. Ohgami, R. S., Campagna, D. R., McDonald, A., Fleming, M. D., The Steap proteins are metalloreductases. Blood 2006, 108, 1388-1394.
62. Anderson, C. P., Shen, M., Eisenstein, R. S., Leibold, E. A., Mammalian iron metabolism and its control by iron regulatory proteins. Biochim. Biophys. Acta 2012, 1823, 1468-1483.
63. Koorts, A. M., Viljoen, M., Ferritin and ferritin isoforms I: structure-function relationships, synthesis, degradation and secretion. Arch. Physiol. Biochem. 2007, 113, 30-54.
64. Watt, R. K., Hilton, R. J., Graff, D. M., Oxido-reduction is not the only mechanism allowing ions to traverse the ferritin protein shell. Biochim. Biophys. Acta 2010, 1800, 745-759.
65. MacKenzie, E. L., Iwasaki, K., Tsuji, Y., Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid. Redox. Signal 2008, 10, 997-1030.
66. Peyssonnaux, C., Nizet, V., Johnson, R. S., Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 2008, 7, 28-32.
67. Ganz, T., Hepcidin and its role in regulating systemic iron metabolism. Hematology Am. Soc. Hematol. Educ. Program 2006, 507, 29-35.
68. Ganz, T., Systemic iron homeostasis. Physiol. Rev. 2013, 93, 1721-1741.
69. Evstatiev, R., Gasche, C., Iron sensing and signalling. Gut 2012, 61, 933-952.
70. Palaneeswari, M. S., Ganesh, M., Karthikeyan, T., Devi, A. J., Mythili, S. V., Hepcidin-minireview. J. Clin. Diagn. Res. 2013, 7, 1767-1771.
71. Ganz, T., Nemeth, E., Hepcidin and iron homeostasis. Biochim. Biophys. Acta 2012, 1823, 1434-1443.
72. Kim, H. J., Khalimonchuk, O., Smith, P. M., Winge, D. R., Structure, function, and assembly of heme centers in mitochondrial respiratory complexes. Biochim. Biophys Acta 2012, 1823, 1604-1616.
73. Lill, R., Hoffmann, B., Molik, S., Pierik, A. J. et al., The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. Biochim. Biophys. Acta 2012, 1823, 1491-1508.
74. Lill, R., Dutkiewicz, R., Elsasser, H. P., Hausmann, A. et al., Mechanisms of iron-sulfur protein maturation in mitochondria, cytosol and nucleus of eukaryotes. Biochim. Biophys. Acta 2006, 1763, 652-667.
75. Hirst, J., Mitochondrial complex I. Annu. Rev. Biochem. 2013, 82, 551-575.
76. Berry, E. A., De Bari, H., Huang, L. S., Unanswered questions about the structure of cytochrome bc1 complexes. Biochim. Biophys. Acta 2013, 1827, 1258-1277.
77. Halestrap, A. P., Clarke, S. J., Khaliulin, I., The role of mitochondria in protection of the heart by preconditioning. Biochim. Biophys. Acta 2007, 1767, 1007-1031.
78. Michael, S., Petrocine, S. V., Qian, J., Lamarche, J. B. et al., Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia. Cerebellum 2006, 5, 257-267.
79. Elas, M., Bielanska, J., Pustelny, K., Plonka, P. M. et al., Detection of mitochondrial dysfunction by EPR technique in mouse model of dilated cardiomyopathy. Free Radic. Biol. Med. 2008, 45, 321-328.
80. Hider, R. C., Kong, X., Iron speciation in the cytosol: an overview. Dalton Trans. 2013, 42, 3220-3229.
81. Buja, L. M., Vela, D., Cardiomyocyte death and renewal in the normal and diseased heart. Cardiovasc. Pathol. 2008, 17, 349-374.
82. Rakusan, K., Cicutti, N., Flanagan, M. F., Changes in the microvascular network during cardiac growth, development, and aging. Cell. Mol. Biol. Res. 1994, 40, 117-122.
83. Leri, A., Kajstura, J., Anversa, P., Role of cardiac stem cells in cardiac pathophysiology: a paradigm shift in human myocardial biology. Circ. Res. 2011, 109, 941-961.
84. Doroshow, J. H., Locker, G. Y., Myers, C. E., Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J. Clin. Invest. 1980, 65, 128-135.
85. Noeman, S. A., Hamooda, H. E., Baalash, A. A., Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats. Diabetol. Metab. Syndr. 2011, 3, 17.
86. van Heerebeek, L., Franssen, C. P., Hamdani, N., Verheugt, F. W. et al., Molecular and cellular basis for diastolic dysfunction. Curr. Heart Fail. Rep. 2012, 9, 293-302.
87. Gao, W. D., Liu, Y., Marban, E., Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium. Circulation 1996, 94, 2597-2604.
88. Dorn, G. W., II, Maack, C., SR and mitochondria: calcium cross-talk between kissing cousins. J. Mol. Cell. Cardiol. 2013, 55, 42-49.
89. Mann, D. L., Topkara, V. K., Evans, S., Barger, P. M., Innate immunity in the adult mammalian heart: for whom the cell tolls. Trans. Am. Clin. Climatol. Assoc. 2010, 121, 34-50; discussion 50-31.
90. Jahns, R., Boivin, V., Schwarzbach, V., Ertl, G. et al., Pathological autoantibodies in cardiomyopathy. Autoimmunity 2008, 41, 454-461.
91. Vallejo, J. G., Role of toll-like receptors in cardiovascular diseases. Clin. Sci. 2011, 121, 1-10.
92. Liu, Y. Y., Cai, W. F., Yang, H. Z., Cui, B. et al., Bacillus Calmette-Guerin and TLR4 agonist prevent cardiovascular hypertrophy and fibrosis by regulating immune microenvironment. J. Immunol. 2008, 180, 7349-7357.
93. Ron, D., Walter, P., Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell. Biol. 2007, 8, 519-529.
94. Vannuvel, K., Renard, P., Raes, M., Arnould, T., Functional and morphological impact of ER stress on mitochondria. J. Cell. Physiol. 2013, 228, 1802-1818.
95. Bravo, R., Parra, V., Gatica, D., Rodriguez, A. E. et al., Endoplasmic reticulum and the unfolded protein response: dynamics and metabolic integration. Int. Rev. Cell. Mol. Biol. 2013, 301, 215-290.
96. Gorman, A. M., Healy, S. J., Jager, R., Samali, A., Stress management at the ER: regulators of ER stress-induced apoptosis. Pharmacol. Ther. 2012, 134, 306-316.
97. Wang, W. A., Groenendyk, J., Michalak, M., Calreticulin signaling in health and disease. Int. J. Biochem. Cell Biol. 2012, 44, 842-846.
98. Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O. et al., Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 2012, 12, 860-875.
99. Hayashi, T., Rizzuto, R., Hajnoczky, G., Su, T. P., MAM: more than just a housekeeper. Trends Cell Biol. 2009, 19, 81-88.
100. Simmen, T., Lynes, E. M., Gesson, K., Thomas, G., Oxidative protein folding in the endoplasmic reticulum: tight links to the mitochondria-associated membrane (MAM). Biochim. Biophys. Acta 2010, 1798, 1465-1473.
101. Bedard, K., Krause, K. H., The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007, 87, 245-313.
102. Paletta-Silva, R., Rocco-Machado, N., Meyer-Fernandes, J. R., NADPH oxidase biology and the regulation of tyrosine kinase receptor signaling and cancer drug cytotoxicity. Int. J. Mol. Sci. 2013, 14, 3683-3704.
103. Ascenzi, P., di Masi, A., Sciorati, C., Clementi, E., Peroxynitrite-An ugly biofactor? Biofactors 2010, 36, 264-273.
104. Ahmad, R., Rasheed, Z., Ahsan, H., Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol. Immunotoxicol. 2009, 31, 388-396.
105. Krysko, O., Love Aaes, T., Bachert, C., Vandenabeele, P. et al., Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013, 4, e631.
106. Garg, A. D., Kaczmarek, A., Krysko, O., Vandenabeele, P. et al., ER stress-induced inflammation: does it aid or impede disease progression? Trends Mol. Med. 2012, 18, 589-598.
107. Ray, P. D., Huang, B. W., Tsuji, Y., Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell. Signal. 2012, 24, 981-990.
108. Kensler, T. W., Wakabayashi, N., Biswal, S., Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 89-116.
109. Kobayashi, A., Kang, M. I., Okawa, H., Ohtsuji, M. et al., Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 2004, 24, 7130-7139.
110. Hybertson, B. M., Gao, B., Bose, S. K., McCord, J. M., Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol. Aspects Med. 2011, 32, 234-246.
111. MacLeod, A. K., McMahon, M., Plummer, S. M., Higgins, L. G. et al., Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 2009, 30, 1571-1580.
112. Ashino, T., Yamanaka, R., Yamamoto, M., Shimokawa, H. et al., Negative feedback regulation of lipopolysaccharide-induced inducible nitric oxide synthase gene expression by heme oxygenase-1 induction in macrophages. Mol. Immunol. 2008, 45, 2106-2115.
113. Kim, Y. W., West, X. Z., Byzova, T. V., Inflammation and oxidative stress in angiogenesis and vascular disease. J. Mol. Med. 2013, 91, 323-328.
114. Gloire, G., Piette, J., Redox regulation of nuclear post-translational modifications during NF-kappaB activation. Antioxid. Redox. Signal. 2009, 11, 2209-2222.
115. Freigang, S., Ampenberger, F., Spohn, G., Heer, S. et al., Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur. J. Immunol. 2011, 41, 2040-2051.
116. Hunnicutt, J., He, K., Xun, P., Dietary iron intake and body iron stores are associated with risk of coronary heart disease in a meta-analysis of prospective cohort studies. J. Nutr. 2014, 144, 359-366.
117. Cook, J. D., Adaptation in iron metabolism. Am. J. Clin. Nutr. 1990, 51, 301-308.
118. Ellervik, C., Tybjaerg-Hansen, A., Grande, P., Appleyard, M. et al., Hereditary hemochromatosis and risk of ischemic heart disease: a prospective study and a case-control study. Circulation 2005, 112, 185-193.
119. Shi, Y., Zhou, L., Huang, L. H., Lian, Y. T. et al., Plasma ferritin levels, genetic variations in HFE gene, and coronary heart disease in Chinese: a case-control study. Atherosclerosis 2011, 218, 386-390.
120. Mascitelli, L., Goldstein, M. R., Hereditary hemochromatosis, iron, hepcidin, and coronary heart disease. Med. Hypotheses 2014, 82, 402-403.
121. Pardo Silva, M. C., Njajou, O. T., Alizadeh, B. Z., Hofman, A. et al., HFE gene mutations increase the risk of coronary heart disease in women. Eur. J. Epidemiol. 2010, 25, 643-649.
122. Mascitelli, L., Goldstein, M. R., Pezzetta, F., Explaining sex difference in coronary heart disease: is it time to shift from the oestrogen hypothesis to the iron hypothesis? J. Cardiovasc. Med. 2011, 12, 64-65.
123. Pan, A., Sun, Q., Bernstein, A. M., Schulze, M. B. et al., Red meat consumption and mortality: results from 2 prospective cohort studies. Arch. Intern. Med. 2012, 172, 555-563.
124. Ascherio, A., Willett, W. C., Rimm, E. B., Giovannucci, E. L. et al., Dietary iron intake and risk of coronary disease among men. Circulation 1994, 89, 969-974.
125. Klipstein-Grobusch, K., Grobbee, D. E., den Breeijen, J. H., Boeing, H. et al., Dietary iron and risk of myocardial infarction in the Rotterdam Study. Am. J. Epidemiol. 1999, 149, 421-428.
126. Kaluza, J., Larsson, S. C., Hakansson, N., Wolk, A., Heme iron intake and acute myocardial infarction: a prospective study of men. Int. J. Cardiol. 2014, 172, 155-160.
127. Demant, A. W., Schmiedel, A., Buttner, R., Lewalter, T. et al., Heart failure and malignant ventricular tachyarrhythmias due to hereditary hemochromatosis with iron overload cardiomyopathy. Clin. Res. Cardiol. 2007, 96, 900-903.
128. Shizukuda, Y., Tripodi, D. J., Zalos, G., Bolan, C. D. et al., Incidence of cardiac arrhythmias in asymptomatic hereditary hemochromatosis subjects with C282Y homozygosity. Am. J. Cardiol. 2012, 109, 856-860.
129. Detterich, J., Noetzli, L., Dorey, F., Bar-Cohen, Y. et al., Electrocardiographic consequences of cardiac iron overload in thalassemia major. Am. J. Hematol. 2012, 87, 139-144.
130. Monte, I., Capodanno, D., Nicolosi, E., Licciardi, S. et al., Atrial and ventricular function in thalassemic patients with supra-ventricular arrhythmias. Heart Int. 2009, 4, e3.
131. Gabutti, V., Piga, A., Results of long-term iron-chelating therapy. Acta Haematol. 1996, 95, 26-36.
132. Fabio, G., Minonzio, F., Delbini, P., Bianchi, A. et al., Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood 2007, 109, 362-364.
133. Felker, G. M., Adams, K. F., Jr., Gattis, W. A., O'Connor, C. M., Anemia as a risk factor and therapeutic target in heart failure. J. Am. Coll. Cardiol. 2004, 44, 959-966.
134. Gaggin, H. K., Dec, G. W., The role of treatment for anemia as a therapeutic target in the management of chronic heart failure: insights after RED-HF. Curr. Treat. Options Cardiovasc. Med. 2014, 16, 279-288.
135. Ruifrok, W. P., Qian, C., Sillje, H. H., van Goor, H. et al., Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin. J. Mol. Med. 2011, 89, 377-387.
136. Jackevicius, C., Fan, C. S., Warner, A., Clinical outcomes of erythropoietin use in heart failure patients with anemia of chronic kidney disease. J. Card. Fail. 2014, 20, 327-333.
137. Hansson, G. K., Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352, 1685-1695.
138. Collin, B., Busseuil, D., Zeller, M., Perrin, C. et al., Increased superoxide anion production is associated with early atherosclerosis and cardiovascular dysfunctions in a rabbit model. Mol. Cell Biochem. 2007, 294, 225-235.
139. Rajendran, R., Minqin, R., Ronald, J. A., Rutt, B. K. et al., Does iron inhibit calcification during atherosclerosis? Free Radic. Biol. Med. 2012, 53, 1675-1679.
140. Minqin, R., Watt, F., Huat, B. T., Halliwell, B., Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions. Free Radic. Biol. Med. 2003, 34, 746-752.
141. Dabbagh, A. J., Shwaery, G. T., Keaney, J. F., Jr., Frei, B., Effect of iron overload and iron deficiency on atherosclerosis in the hypercholesterolemic rabbit. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 2638-2645.
142. Minqin, R., Rajendran, R., Pan, N., Tan, B. K. et al., The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic. Biol. Med. 2005, 38, 1206-1211.
143. Duffy, S. J., Biegelsen, E. S., Holbrook, M., Russell, J. D. et al., Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001, 103, 2799-2804.
144. Wu, B. J., Kathir, K., Witting, P. K., Beck, K. et al., Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J. Exp. Med. 2006, 203, 1117-1127.
145. Benderitter, M., Maupoil, V., Vergely, C., Dalloz, F. et al., Studies by electron paramagnetic resonance of the importance of iron in the hydroxyl scavenging properties of ascorbic acid in plasma: effects of iron chelators. Fundam. Clin. Pharmacol. 1998, 12, 510-516.
146. Kontoghiorghes, G. J., Pattichis, K., Neocleous, K., Kolnagou, A., The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr. Med. Chem. 2004, 11, 2161-2183.